3'-Phosphoadenosine-5'-phosphosulphate

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 英文名称: 3'-Phosphoadenosine-5'-phosphosulphate
• 英文别名: [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] sulfo hydrogen phosphate
• 化学式: C₁₀H₁₅N₅O₁₃P₂S
• 分子量: 507.268
• InChiKey: GCWYYXZQNSUOEN-KQYNXXCUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  284
• 氢给体数：
  6
• 氢受体数：
  17

反应信息

• 作为产物：
  描述：

  5’-三磷酸腺苷 在 rat brain cytosolic fraction 、 magnesium 、 sodium sulfate 作用下， 以 水 为溶剂， 反应 0.17h， 生成 3'-Phosphoadenosine-5'-phosphosulphate
  参考文献：
  名称：

  N-sulphation of desipramine in the rat brain

  摘要：

  1. Amine N-sulphotransferase (NST) activity with desipramine (DMI) as substrate was assayed in vitro in various areas of the rat brain. Biosynthesis of 3'-phosphoadenosine-5'-phospho(35)sulphate (PAPS) from sodium (35)sulphate and ATP was also measured by coupling it to the sulphation of minoxidil by minoxidil sulphotransferase (MST).2. For the DMI-NST reaction, an apparent K-m = 0.5 mM was obtained for DMI and two apparent K(m)s = 0.3 and 1.7 mu M for PAPS, whereas in the PAPS-generating reactions, the K-m for sodium (35)sulphate = 20 mu M.3. Both the enzyme activities were widely distributed in rat brain. The rate of NST activity was 2-3 orders of magnitude lower than that of PAPS generation. N-sulphoconjugation of DMI, which is proposed as a possible biotransformation pathway of DMI in the rat brain, could conceivably be supported adequately by the 'active sulphate' generated within the same areas of the brain.

  DOI：

  10.3109/00498259609046685

文献信息

• Novel class of sterol ligands and their uses in regulation of cholesterol and gene expression
  申请人：Javitt B. Norman

  公开号：US20060121024A1

  公开（公告）日：2006-06-08

  This invention relates to oxysteroids and oxysteroid hormones which have been identified. These oxysteroids are C27 modified sterols, particularly derivatives of intermediates in cholesterol synthesis, including lanosterol, zymosterol and desmosterol, including C27 diol and C27 acid derivatives, as well as related compounds and analogs thereof. The oxysteroids are capable of binding to or otherwise interacting with orphan nuclear receptors to result in modulation of gene expression. The invention further relates to methods of modulating the rate of cholesterol synthesis in a mammal. More specifically, the invention relates to treatment of cholesterol-related conditions which are improved or ameliorated by modulating the rate of cholesterol synthesis or cholesterol metabolism in a human in need thereof by administration of these oxysteroids, analogs or antagonists thereof. The invention includes methods for ameliorating, treating or preventing macular degeneration in a mammal comprising administering to said mammal an agent which stimulates or enhances the expression or activity of steroid sulphotransferase (SLUT2), particularly SLUT2B1b, or which stimulates or enhances the expression or activity of CYP27A1 or sterol 27-hydroxylase or otherwise increasing the sulfonation or 27-hydroxylation of cholesterol intermediates, including 7-ketocholesterol. Assays for identification of analogs, antagonists or modulators of these oxysteroids or of sterol 27-hydroxylase are also provided.

  本发明涉及已经鉴定的氧化甾体和氧化甾体激素。这些氧化甾体是C27修饰类固醇，特别是胆固醇合成中间体的衍生物，包括鲸蜡醇、酵母蜡醇和脱酸酶醇，包括C27二醇和C27酸衍生物，以及相关化合物和类似物。这些氧化甾体能够与孤儿核受体结合或以其他方式相互作用，从而调节基因表达。本发明进一步涉及在哺乳动物中调节胆固醇合成速率的方法。更具体地，本发明涉及通过给予这些氧化甾体、类似物或其拮抗剂来改善或缓解需要调节胆固醇合成或胆固醇代谢速率的人类的与胆固醇相关的疾病的治疗。本发明包括治疗、改善或预防哺乳动物黄斑退化的方法，包括给予一种刺激或增强类固醇硫酸转移酶（SLUT2），特别是SLUT2B1b，表达或活性的药物，或者刺激或增强CYP27A1或类固醇27-羟化酶的表达或活性，或以其他方式增加胆固醇中间体的磺酸化或27-羟化，包括7-酮胆固醇。还提供了用于鉴定这些氧化甾体或类固醇27-羟化酶的类似物、拮抗剂或调节剂的测定方法。
• Treatment of tumours
  申请人：Hagstrom Tomas

  公开号：US20050192262A1

  公开（公告）日：2005-09-01

  The present invention refers to steroid derivatives for use as medicaments. More specifically, the invention also relates to the use of a steroid derivative of 5-androstene-, 5-pregnenolone or corresponding saturated derivatives (androstane- or pregnane-) in the manufacture of a medicament for the treatment of a benign and/or malignant tumour, which medicament is capable of interrupting disturbances in Wnt-signaling, such as cell-cycle arrest in G1-phase, and/or providing an angiostatic effect. Examples of such steroid derivatives are -5-androstene-17-ol, androstane-17-ol-pregnane-17-ol or pregnane-17-ol derivatives. In a further aspect, the invention relates to a method of producing a medicament for the treatment of a benign and/or malignant tumour and/or an inflammatory condition comprising the steps of contacting 5-androstane-3β,17-diol or androstane-3β-diol, an enzyme and a sulfotransferase to provide 5-androstene-17-ol-3β-sulfate or corresponding andros tane derivative (17-AEDS or 17-AADS); and mixing the 17-AEDS or 17-AADS so produced with a suitable carrier; whereby a medicament which is capable of acting as a ligand to peroxisome proliferators-activated receptor-(PPAR) is produced.

  本发明涉及类固醇衍生物作为药物的使用。更具体地说，本发明还涉及在制造用于治疗良性和/或恶性肿瘤的药物中使用5-雄烯-、5-孕酮或相应饱和衍生物（雄烷-或孕烷-）的类固醇衍生物，该药物能够中断Wnt信号传导中的干扰，例如在G1期细胞周期停滞，并/或提供抗血管生成效应。此类类固醇衍生物的例子包括-5-雄烯-17-醇、雄烷-17-醇-孕烷-17-醇或孕烷-17-醇衍生物。在另一方面，本发明还涉及一种制造用于治疗良性和/或恶性肿瘤和/或炎症状态的药物的方法，包括以下步骤：将5-雄烷-3β,17-二醇或雄烷-3β-二醇、酶和硫酸转移酶接触，以提供5-雄烯-17-醇-3β-硫酸酯或相应的雄烷衍生物（17-AEDS或17-AADS）；并将所生产的17-AEDS或17-AADS与适当的载体混合；从而产生能够作为过氧化物酶体增殖物激活受体-（PPAR）配体的药物。
• TREATMENT OF TUMOURS
  申请人：Hagstrom Tomas

  公开号：US20070111973A1

  公开（公告）日：2007-05-17

  The present invention refers to steroid derivatives for use as medicaments. More specifically, the invention also relates to the use of a steroid derivative of 5-androstene-, 5-pregnenolone or corresponding saturated derivatives (androstane- or pregnane-) in the manufacture of a medicament for the treatment of a benign and/or malignant tumour, which medicament is capable of interrupting disturbances in Wut-signaling, such as cell-cycle arrest in G1-phase, and/or providing an angiostatic effect. Examples of such steroid derivatives are -5-androstene-17-ol, androstane-17-ol-pregnane-17-ol or pregnane-17-ol derivatives. In a further aspect, the invention relates to a method of producing a medicament for the treatment of a benign and/or malignant tumour and/or an inflammatory condition comprising the steps of contacting 5-androstane-3B,17-dio 1 or androstane-3B-diol, an enzyme and a sulfotransferase to provide 5-androstene-17-ol-3B-sulfate or corresponding andros tane derivative (17-AEDS or 17-AADS); and mixing the 17-AEDS or 17-AADS so produced with a suitable carrier; whereby a medicament which is capable of acting as a ligand to peroxisome proliferators-activated receptor—(PPAR) is produced.

  本发明涉及类固醇衍生物用作药物。更具体地，本发明还涉及在制造用于治疗良性和/或恶性肿瘤的药物中使用5-雄烯烷，5-孕酮或相应饱和衍生物（雄烷或孕烷）的类固醇衍生物，该药物能够中断Wut信号传导的紊乱，例如在G1期细胞周期停滞，并/或提供血管生成抑制作用。此类类固醇衍生物的例子是-5-雄烯烷-17-醇，雄烷-17-醇-孕烷-17-醇或孕烷-17-醇衍生物。此外，本发明还涉及一种用于制备用于治疗良性和/或恶性肿瘤和/或炎症症状的药物的方法，包括以下步骤：接触5-雄烷-3B，17-二酮或雄烷-3B-二醇，一种酶和一种硫酸转移酶，以提供5-雄烯烷-17-醇-3B-硫酸酯或相应的雄烷衍生物（17-AEDS或17-AADS）;并将所生产的17-AEDS或17-AADS与适当的载体混合；从而制备出能够作为过氧化物酶体增殖物激活受体-（PPAR）配体的药物。
• METHOD FOR DETERMINATION OF ENZYMATIC ACTIVITY
  申请人：Yamamoto Koji

  公开号：US20090104627A1

  公开（公告）日：2009-04-23

  A novel modified polysaccharide, a solid phase to which the polysaccharide is adhered, methods for detecting N-deacetylase activity, N-sulfotransferase activity and N-deacetylase/N-sulfotransferase activity in a sample which utilizes said solid phase, and detection kits thereof.

  一种新型改性多糖，其中多糖附着在固相上，用于检测样品中N-脱乙酰酰胺酶活性、N-硫酰转移酶活性和N-脱乙酰酰胺酶/N-硫酰转移酶活性的方法，以及使用该固相的检测工具箱。
• Methods for monitoring multiple gene expression
  申请人：Bolotine Alexandre

  公开号：US20100267584A1

  公开（公告）日：2010-10-21

  The present invention relates to methods for monitoring differential expression of a plurality of genes in a first Bacillus cell relative to expression of the same genes in one or more second Bacillus cells using microarrays containing Bacillus genomic sequenced tags. The present invention also relates to computer readable media and computer-based systems. The present invention further relates to substrates containing an array of Bacillus licheniformis or Bacillus clausii GSTs.

  本发明涉及使用包含巴氏杆菌基因组序列标签的微阵列，监测第一株巴氏杆菌细胞相对于一个或多个第二株巴氏杆菌细胞中相同基因的表达差异的方法。本发明还涉及计算机可读介质和基于计算机的系统。本发明还涉及含有巴氏地衣菌或克劳斯氏杆菌GSTs阵列的基质。